药物耐药性症中的性饮食:临床营养评估
Cecilia Nascimento de Mendonça1, Adelia Maria de Miranda Henriques-Souza2, Larissa de Andrade Viana2
1Instituto de Medicina Integral Prof. Fernando Figueira, Programa de Graduação Stricto Sensu do IMIP, Recife PE, Brazil.
Arquivos de neuro-psiquiatria
|February 23, 2024
概括
性饮食改善了患有的体重不足儿童的营养状况,并减少了发作的频率. 这种饮食疗法是治疗儿科及其相关营养挑战的宝贵选择.
科学领域:
- 神经学 神经学
- 儿科医学 儿科医学
- 营养科学 营养科学
背景情况:
- 是一种常见的儿童神经系统疾病,大约30%的病例表现出耐药性发作.
- 由于饮食限制,反复发作会对营养状况产生负面影响.
- 很少有研究研究了诸如性饮食治疗等非药物干预措施对患有的儿童和青少年营养状况的影响.
研究的目的:
- 评估基因饮食对药物耐药的儿科患者营养状况和临床结果的影响.
- 为了评估性饮食在管理营养挑战以及控制发作方面的作用.
主要方法:
- 进行了一项横截面研究,涉及49名18岁以下的患者,这些患者接受了基因饮食门诊诊所的治疗.
- 关于社会经济,临床,营养和实验室参数的数据是从医疗记录中追溯收集的.
- 在基因饮食治疗期间,在不同时间点分析了患者数据.
主要成果:
- 体重不足的患者 (n=49,中位数年龄4.4岁) 经过六个月的饮食后,BMI-for-age有所改善.
- 体重正常或超重的患者保持了他们的营养状况.
- 失脂症是一种常见的,短暂的不良反应;然而,发作频率和抗药物的使用减少.
结论:
- 性饮食有效地预防了儿科患者营养不良的恶化.
- 性饮食疗法显著降低了发作频率和需要抗药物的需要.
- 这种干预提供了改善营养状况和控制症儿童发作的双重好处.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183
Arteries of the Lower Limbs
189
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
189
Antiepileptic Drugs: Glutamate Antagonists
355
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
355
Antiepileptic Drugs: GABAergic Pathway Potentiators
399
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
399
Antiepileptic Drugs: Sodium Channel Blockers
559
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
559
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
301
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
301


